RGEN - Repligen Corporation

RGEN - Repligen Corporation

https://www.repligen.com

Momentum: Bearish

Recent News

Powered by Alpha Vantage

Repligen Corporation to Present at Upcoming September Conferences - Repligen ( NASDAQ:RGEN )

Benzinga • 3 weeks, 3 days ago • score: 0.22

WALTHAM, Mass., Aug. 22, 2025 ( GLOBE NEWSWIRE ) -- Repligen Corporation RGEN, a life sciences company focused on bioprocessing technology leadership, today announced that it will be attending three upcoming investor conferences. The Wells Fargo Healthcare Conference, being held September 3 - ...

Do Options Traders Know Something About Repligen Stock We Don't?

Zacks Commentary • 3 weeks, 5 days ago • score: 0.10

Investors need to pay close attention to RGEN stock based on the movements in the options market lately.

Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick

Zacks Commentary • 1 month, 1 week ago • score: 0.48

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Repligen Stock Outlook: Risk Skewed To The Downside Through 2026 - Repligen ( NASDAQ:RGEN )

Benzinga • 1 month, 2 weeks ago • score: -0.29

Repligen RGEN has been in a steady downtrend for over 1400 days. Adhishthana principles suggest the weakness is likely to continue. Here's a breakdown of the stock's current structure. According to Adhishthana principles, a stock typically breaks out of its Cakra pattern in Phase 9, which starts ...

Repligen Announces Strategic Partnership with Novasign to Further Advance Bioprocessing Digitalization - Repligen ( NASDAQ:RGEN )

Benzinga • 1 month, 2 weeks ago • score: 0.28

WALTHAM, Mass., July 31, 2025 ( GLOBE NEWSWIRE ) -- Repligen Corporation RGEN, a life sciences company focused on bioprocessing technology leadership, today announced Novasign and Repligen have entered into a strategic partnership to develop and integrate Novasign's machine learning and modeling ...

Here's Why Repligen ( RGEN ) is a Strong Growth Stock

Zacks Commentary • 1 month, 3 weeks ago • score: 0.48

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Repligen to Report Second Quarter 2025 Financial Results - Repligen ( NASDAQ:RGEN )

Benzinga • 1 month, 4 weeks ago • score: 0.09

WALTHAM, Mass., July 17, 2025 ( GLOBE NEWSWIRE ) -- Repligen Corporation RGEN today announced that the Company will report its second quarter 2025 financial results on Tuesday, July 29, 2025. The Company will issue a press release before the market opens and will host a conference call at 8:30 ...

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

Repligen Corporation develops and markets bioprocessing systems and technologies for use in the biologic drug manufacturing process in North America, Europe, Asia Pacific, and internationally. The company is headquartered in Waltham, Massachusetts.

52W High

$182.52

52W Low

$102.97

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

1.07

Valuation

Rich

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

60.61

EV/EBITDA (<8 favorable)

70.19

EV/Revenue (<3 favorable)

10.36

P/S (TTM) (<3 favorable)

10.40

P/B (<3 favorable)

3.40

Ownership

Institution‑heavy

Source: Overview

Insiders (1–5% typical)

6.39%

Institutions (25–75% balanced)

104.80%

Shares Outstanding

56,258,000

Float

52,655,000

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

673,956,000

Gross Profit (TTM)

343,650,000

EPS (TTM)

-0.25

Profit Margin (>10% good)

-0.02%

Operating Margin (TTM) (higher better)

0.05%

ROE (TTM) (>15% strong)

-0.01%

EPS YoY (Quarterly) (>10% good)

1.60

Revenue YoY (Quarterly) (>8% good)

0.15

Momentum

Bearish momentum

Value

-1.0006

Previous

-0.2845

Trend

Falling

Signal Cross

No cross

As of

Sep. 12, 2025